Tag: RANKL pathway
Multiple Myeloma Bone Disease: Current Treatments and Emerging Novel Agents
Multiple myeloma bone disease affects over 80% of patients, causing fractures and pain. Current treatments like bisphosphonates and denosumab help but have limitations. New drugs targeting RANKL, DKK1, and sclerostin show promise. Patients face side effects and costs. Future therapies aim to heal bone damage.